Your browser doesn't support javascript.
loading
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Hedegaard, Jakob; Lamy, Philippe; Nordentoft, Iver; Algaba, Ferran; Høyer, Søren; Ulhøi, Benedicte Parm; Vang, Søren; Reinert, Thomas; Hermann, Gregers G; Mogensen, Karin; Thomsen, Mathilde Borg Houlberg; Nielsen, Morten Muhlig; Marquez, Mirari; Segersten, Ulrika; Aine, Mattias; Höglund, Mattias; Birkenkamp-Demtröder, Karin; Fristrup, Niels; Borre, Michael; Hartmann, Arndt; Stöhr, Robert; Wach, Sven; Keck, Bastian; Seitz, Anna Katharina; Nawroth, Roman; Maurer, Tobias; Tulic, Cane; Simic, Tatjana; Junker, Kerstin; Horstmann, Marcus; Harving, Niels; Petersen, Astrid Christine; Calle, M Luz; Steyerberg, Ewout W; Beukers, Willemien; van Kessel, Kim E M; Jensen, Jørgen Bjerggaard; Pedersen, Jakob Skou; Malmström, Per-Uno; Malats, Núria; Real, Francisco X; Zwarthoff, Ellen C; Ørntoft, Torben Falck; Dyrskjøt, Lars.
Afiliação
  • Hedegaard J; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Lamy P; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Nordentoft I; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Algaba F; Section of Pathology, Fundació Puigvert, University Autonoma de Barcelona, Barcelona 08025, Spain.
  • Høyer S; Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark.
  • Ulhøi BP; Department of Pathology, Aarhus University Hospital, Aarhus 8000, Denmark.
  • Vang S; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Reinert T; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Hermann GG; Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark.
  • Mogensen K; Department of Urology, Frederiksberg Hospital, Frederiksberg 2000, Denmark.
  • Thomsen MBH; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Nielsen MM; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Marquez M; Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
  • Segersten U; Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden.
  • Aine M; Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund 22100, Sweden.
  • Höglund M; Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund 22100, Sweden.
  • Birkenkamp-Demtröder K; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Fristrup N; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Borre M; Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Stöhr R; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Wach S; Department of Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Keck B; Department of Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Seitz AK; Department of Urology, Klinikum rechts der Isar der Technischen Universität München, Munich 81675, Germany.
  • Nawroth R; Department of Urology, Klinikum rechts der Isar der Technischen Universität München, Munich 81675, Germany.
  • Maurer T; Department of Urology, Klinikum rechts der Isar der Technischen Universität München, Munich 81675, Germany.
  • Tulic C; Faculty of Medicine, Clinic of Urology, Clinical Centre of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
  • Simic T; Faculty of Medicine, Institute of Medical and Clinical Biochemistry, University of Belgrade, 11000 Belgrade, Serbia.
  • Junker K; Department of Urology, Saarland University, Homburg 66421, Germany.
  • Horstmann M; Department of Urology, Friedrich-Schiller-University Jena, Jena 07737, Germany.
  • Harving N; Department of Urology, Aalborg University Hospital, Aalborg 9000, Denmark.
  • Petersen AC; Department of Pathology, Aalborg University Hospital, Aalborg 9000, Denmark.
  • Calle ML; Systems Biology Department, University of Vic, Vic, Barcelona 08500, Spain.
  • Steyerberg EW; Department of Public Health, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands.
  • Beukers W; Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands.
  • van Kessel KEM; Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands.
  • Jensen JB; Department of Urology, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Pedersen JS; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Malmström PU; Department of Surgical Sciences, Uppsala University, Uppsala 75185, Sweden.
  • Malats N; Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
  • Real FX; Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08003, Spain.
  • Zwarthoff EC; Department of Pathology, Erasmus Medical Centre, 3015 CE Rotterdam, the Netherlands.
  • Ørntoft TF; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark.
  • Dyrskjøt L; Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: lars@clin.au.dk.
Cancer Cell ; 30(1): 27-42, 2016 07 11.
Article em En | MEDLINE | ID: mdl-27321955
ABSTRACT
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely different outcomes. We performed a comprehensive transcriptional analysis of 460 early-stage urothelial carcinomas and showed that NMIBC can be subgrouped into three major classes with basal- and luminal-like characteristics and different clinical outcomes. Large differences in biological processes such as the cell cycle, epithelial-mesenchymal transition, and differentiation were observed. Analysis of transcript variants revealed frequent mutations in genes encoding proteins involved in chromatin organization and cytoskeletal functions. Furthermore, mutations in well-known cancer driver genes (e.g., TP53 and ERBB2) were primarily found in high-risk tumors, together with APOBEC-related mutational signatures. The identification of subclasses in NMIBC may offer better prognostication and treatment selection based on subclass assignment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Biomarcadores Tumorais / Análise de Sequência de RNA / Perfilação da Expressão Gênica / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Biomarcadores Tumorais / Análise de Sequência de RNA / Perfilação da Expressão Gênica / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Dinamarca